Compare Natera Inc. Common Stock (NTRA) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Oatly Group AB - ADR — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Oatly Group AB - ADR trades at $11.1 (market cap $355.50M). The key difference: Natera Inc. Common Stock is far larger — about 160.4× Oatly Group AB - ADR's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Oatly Group AB - ADR for 18 Days on average.
| NTRA | OTLY | |
|---|---|---|
Market Cap | $57.03B | $355.50M |
Volume | 1,131,157 | 70,853 |
Sector | Health | Consumer Staples |
52-Week High | $425.64 | $15.91 |
52-Week Low | $179.42 | $8.03 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $56.18B | $859.91M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
OTLY trades at $10.88, up 1.97% today, with a bearish technical signal despite a neutral RSI. Revenue grew to $862M in 2025, but net losses persist at -$153M. The company shows improving margins and raised its 2026 revenue outlook after Q2 results. Analyst consensus is mixed with a $12.28 price target, indicating modest upside potential.
The outlook hinges on OTLY's path to profitability amid high debt and negative cash flows. While product innovation and distribution gains offer growth catalysts, the stock faces risks from sustained losses and competitive pressures. Investors should weigh the turnaround progress against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
